{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Injectable+Placebo&page=116",
    "query": {
      "intervention": "Injectable Placebo",
      "page": 116
    },
    "page_size": 10
  },
  "pagination": {
    "page": 116,
    "page_size": 10,
    "total_count": 4227,
    "total_pages": 423,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Injectable+Placebo&page=117&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Injectable+Placebo&page=115&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-13T00:39:46.843Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01640912",
      "title": "Evaluation of the Safety, Pharmacokinetics, and Preliminary Effect on Scar Formation by RXI-109",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cicatrix",
        "Scar Prevention"
      ],
      "interventions": [
        {
          "name": "RXI-109",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "RXi Pharmaceuticals, Corp.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "50 Years",
        "sex": "FEMALE",
        "summary": "21 Years to 50 Years · Female only"
      },
      "enrollment_count": 15,
      "start_date": "2012-06",
      "completion_date": "2014-05",
      "has_results": false,
      "last_update_posted_date": "2014-09-17",
      "last_synced_at": "2026-11-13T00:39:46.843Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01640912"
    },
    {
      "nct_id": "NCT04042727",
      "title": "Controlling Rapid Atrial Fibrillation With Dexmedetomidine",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Rapid Atrial Fibrillation",
        "Heart Rate Control"
      ],
      "interventions": [
        {
          "name": "Dexmedetomidine Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Normal Saline",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Stony Brook University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 13,
      "start_date": "2019-08-21",
      "completion_date": "2021-12-31",
      "has_results": true,
      "last_update_posted_date": "2024-06-04",
      "last_synced_at": "2026-11-13T00:39:46.843Z",
      "location_count": 1,
      "location_summary": "Stony Brook, New York",
      "locations": [
        {
          "city": "Stony Brook",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04042727"
    },
    {
      "nct_id": "NCT06387394",
      "title": "A Study to Assess BOTOX Injections in Adult Participants for the Change of Masseter Muscle Prominence",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Masseter Muscle Prominence"
      ],
      "interventions": [
        {
          "name": "BOTOX",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 202,
      "start_date": "2024-04-22",
      "completion_date": "2025-11-25",
      "has_results": false,
      "last_update_posted_date": "2026-08-25",
      "last_synced_at": "2026-11-13T00:39:46.843Z",
      "location_count": 20,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 17 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06387394"
    },
    {
      "nct_id": "NCT02837575",
      "title": "Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Herpes Genitalis"
      ],
      "interventions": [
        {
          "name": "VCL-HB01",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Phosphate-buffered saline",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Vical",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 261,
      "start_date": "2016-09",
      "completion_date": "2018-12",
      "has_results": false,
      "last_update_posted_date": "2019-02-27",
      "last_synced_at": "2026-11-13T00:39:46.843Z",
      "location_count": 15,
      "location_summary": "Birmingham, Alabama • San Diego, California • Hollywood, Florida + 12 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "South Miami",
          "state": "Florida"
        },
        {
          "city": "West Palm Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02837575"
    },
    {
      "nct_id": "NCT05969223",
      "title": "Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Genital Psoriasis",
        "Scalp Psoriasis"
      ],
      "interventions": [
        {
          "name": "Risankizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo for Risankizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 214,
      "start_date": "2023-08-10",
      "completion_date": "2025-11-28",
      "has_results": true,
      "last_update_posted_date": "2026-02-24",
      "last_synced_at": "2026-11-13T00:39:46.843Z",
      "location_count": 38,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Encino, California + 32 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05969223"
    },
    {
      "nct_id": "NCT00554359",
      "title": "A Dose Escalation and Safety Study of I5NP in Patients Undergoing Major Cardiovascular Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Injury of Kidney",
        "Acute Renal Failure"
      ],
      "interventions": [
        {
          "name": "I5NP (a small interfering RNA)",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Quark Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "21 Years to 85 Years"
      },
      "enrollment_count": 16,
      "start_date": "2007-08",
      "completion_date": "2010-11",
      "has_results": false,
      "last_update_posted_date": "2011-02-23",
      "last_synced_at": "2026-11-13T00:39:46.843Z",
      "location_count": 6,
      "location_summary": "Washington D.C., District of Columbia • Boston, Massachusetts • Cleveland, Ohio + 3 more",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00554359"
    },
    {
      "nct_id": "NCT00402077",
      "title": "A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Overweight",
        "Obesity"
      ],
      "interventions": [
        {
          "name": "pramlintide acetate",
          "type": "DRUG"
        },
        {
          "name": "sibutramine",
          "type": "DRUG"
        },
        {
          "name": "phentermine",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 258,
      "start_date": "2006-11",
      "completion_date": "2007-08",
      "has_results": false,
      "last_update_posted_date": "2015-03-06",
      "last_synced_at": "2026-11-13T00:39:46.843Z",
      "location_count": 16,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Chula Vista, California + 13 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00402077"
    },
    {
      "nct_id": "NCT06632457",
      "title": "LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Metabolic Dysfunction Associated Steatohepatitis"
      ],
      "interventions": [
        {
          "name": "Survodutide",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Placebo matching survodutide",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1590,
      "start_date": "2024-11-12",
      "completion_date": "2029-06-05",
      "has_results": false,
      "last_update_posted_date": "2026-11-12",
      "last_synced_at": "2026-11-13T00:39:46.843Z",
      "location_count": 127,
      "location_summary": "Chandler, Arizona • Peoria, Arizona • Scottsdale, Arizona + 99 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06632457"
    },
    {
      "nct_id": "NCT02725957",
      "title": "A Study to Establish Safety and Maximum Tolerated Dose of IV Trehalose in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteer Subjects"
      ],
      "interventions": [
        {
          "name": "Trehalose for IV Infusion",
          "type": "DRUG"
        },
        {
          "name": "Saline 0.9% IV",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bioblast Pharma Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 24,
      "start_date": "2016-03",
      "completion_date": "2016-08",
      "has_results": false,
      "last_update_posted_date": "2016-11-22",
      "last_synced_at": "2026-11-13T00:39:46.843Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02725957"
    },
    {
      "nct_id": "NCT00235820",
      "title": "Safety and Efficacy of Adalimumab to Methotrexate and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Psoriasis"
      ],
      "interventions": [
        {
          "name": "adalimumab",
          "type": "DRUG"
        },
        {
          "name": "MTX",
          "type": "DRUG"
        },
        {
          "name": "placebo adalimumab, placebo MTX",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Abbott",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 271,
      "start_date": "2005-07",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2008-07-17",
      "last_synced_at": "2026-11-13T00:39:46.843Z",
      "location_count": 1,
      "location_summary": "Abbott Park, Illinois",
      "locations": [
        {
          "city": "Abbott Park",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00235820"
    }
  ]
}